

Think Almac... NeoPeptides™

High throughput peptide manufacturing for immuno-oncology platforms

- MHRA inspected & audited GMP manufacturing facility
- Full CMC documentation support for IND/IMPD submission
- Individualised vaccine patient sets manufactured in less than 3 weeks
- Shared antigen & individualised neoantigen manufacturing capabilities
- Ultra high throughput manufacture for cell therapy applications



NeoPeptides™

A paradigm shift is required in order to provide GMP quality peptides in the short timescales that are demanded for personalised cancer vaccines. We have expanded the paradigm to include ultra high throughput manufacture and rapid GMP manufacture for early phase projects.

Background

NeoPeptides™ are peptides derived from neoantigens, created in tumour cells as a result of mutations which allow the immune system to distinguish cancer cells from non-cancer cells. Almac has extensive expertise in the manufacture of NeoPeptides™:

- Rapid supply of peptides for individualised cancer vaccines, delivering patient sets in < 3 weeks and minimising needle to needle time
- Utilisation of innovative and reliable manufacturing processes and a streamlined testing and control strategy creating the capacity for manufacture and release at a rate of >> 1 GMP peptide per day
- Successful delivery of thousands of NeoPeptides™ across Europe and US, presented as individual peptides or peptide pools.

Almac supplies NeoPeptides™ products from a purpose-built facility configured for speed and cost effective GMP peptide manufacture. Key to the success of this manufacturing philosophy are:

- Specifically designed pharmaceutical quality system, with embedded QA and a focus on patient safety and product integrity
- Robust platform manufacturing processes which are tuned for speed and minimum cost utilising single unit operation throughout and electronic batch records for maximum efficiency
- Streamlined, fit-for-purpose QC strategy

Ultra high throughput peptide manufacture

Ultra high throughput manufacture of peptides as raw materials for cell therapy applications:

- Employs 96-well plate technology and can generate 100s of peptides per week with a low attrition rate
- Rapid QC
- Suitable for cell therapy applications requiring individual peptides, peptide mixtures or both

Rapid GMP manufacture for early phase peptide projects:

Ultra high throughput manufacture of peptides as raw materials for cell therapy applications:

- The NeoPeptides™ offering may be applied to facilitate rapid GMP peptide supply suitable for early phase clinical applications:
- Suitable for projects with low quantity requirements (gram scale)
- High throughput philosophy significantly reduces manufacturing times.
- A cost-effective opportunity for early phase clinical supply



almacgroup.com

Get in touch

Global HQ
+44 28 3836 2436

Edinburgh, UK
+44 28 3839 5717

US HQ
+1 215 660 8500

peptides@almacgroup.com